Trial Profile
A PHASE 2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE (BNT162b2) AGAINST COVID-19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 17 Jul 2023
Price :
$35
*
At a glance
- Drugs Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors BioNTech
- 22 Aug 2022 Status changed from active, no longer recruiting to completed.
- 15 May 2022 Planned End Date changed from 24 Aug 2022 to 26 Jul 2022.
- 15 May 2022 Planned primary completion date changed from 24 Aug 2022 to 26 Jul 2022.